Clinical trial
Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers
NCT00143741 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00143741 |
|---|---|
| Title | Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers |
| Official title | Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers |
| Lead sponsor | University of Chicago, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | End-Stage Kidney Disease |
| Intervention type | Drug |
| Interventions | Atorvastatin (Lipitor) |
| Enrollment | 20 |
| Start date | May 1, 2005 |
| Primary completion | Dec 1, 2010 |
| Completion | Jul 1, 2011 |
| First posted | Sep 2, 2005 |
| Last update posted | Jan 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: